Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

325.62 +12.90 (+4.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Eli Lilly Shares Positive Tirzepatide Data At EASD Annual Meeting
Eli Lilly And Co (NYSE: LLY) posted data from the SURPASS-3 CGM sub-study of tirzepatide in a subpopulation of 243 participants who wore continuous glucose... 
Via Benzinga
Citi Upgrades This Big Pharma Stock On Positive Alzheimer's Expectations
Citi upgraded Eli Lilly And Co (NYSE:LLY) t... 
Via Benzinga
Why Eli Lilly Shares Are Moving Higher Today
Eli Lilly And Co (NYSE: LLY) is trading higher Wednesday after Citigroup analyst Andrew Baum upgraded the stock from a Neutral rating to a Buy rating and raised the ... 
Via Benzinga
What 8 Analyst Ratings Have To Say About Eli Lilly
Within the last quarter, Eli Lilly (NYSE:LLY) has observed the following anal... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021
Upgrades For Spirit AeroSystems Holdings Inc (NYSE: 
Via Benzinga
FDA Expands Lilly's Erbitux Label For Colorectal Cancer Setting
The FDA has approved Eli Lilly And Co's (NYSE: LLY) new indication for Erbitux (cetuximab injection) combined with Pfizer Inc's (NYSE: PFE)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
10 Biggest Price Target Changes For Wednesday
Barclays cut Micron Technology, Inc. (NASDAQ:MU) pr... 
Via Benzinga
3 Growth Stocks That Can Help You Retire Early
Not only are they growing and profitable businesses, but they also pay dividends. 
Via The Motley Fool
Topics Retirement
Exposures Pension
3 COVID Stocks Ready to Take On the Delta Variant
If the COVID mutation takes a turn for the worse, what stocks will protect your port? Our trio of Fools has three suggestions. 
Via The Motley Fool
Exposures COVID-19
Eli Lilly Recalls Batch Of Low Blood Sugar Med Due To Health Risk
Eli Lilly And Co (NYSE: LLY) has recalled one lot of an injectable prescription drug used to treat hypoglycemia, blood glucose levels that have dropped too low,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Where to Invest $10,000 in a Bear Market
For now, both of these high-quality companies may be a bit overvalued, but that could change. 
Via The Motley Fool
A Day Of Huge Market Moves
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 
Via Talk Markets
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
Mirati Therapeutics easily beat Amgen's test results in colon cancer. 
Via Investor's Business Daily
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily... 
Via Benzinga
Visualizing the World’s Biggest Pharmaceutical Companies
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
Why AbCellera Biologics Stock Jumped 7% on Wednesday
The company's drug-development technology is starting to attract attention. 
Via The Motley Fool
Exposures COVID-19
After Regeneron, US Govt. Orders For Additional COVID-19 Therapy From Eli Lilly
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related... 
Via Benzinga
Exposures COVID-19
U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy
The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Read Next: ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback
There's a one-word answer: delta. 
Via The Motley Fool
Exposures COVID-19
Baird Initiates BeyondSpring With Outperform On Plinabulin Potential
BeyondSpring Inc’s (NASDAQ:BYSI) lead candidate plin... 
Via Benzinga
Here's Why ProQR Stock Surged on Thursday
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) shares ... 
Via Benzinga
Why Shares of Johnson & Johnson Are Down 2% Today
The list of ideas is only the start of the legislative process. 
Via The Motley Fool
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
Biogen Stock Dives As CEO Admits 'Slower Than We Anticipated' Alzheimer's Drug Launch
Biogen stock tumbled Thursday after its CEO admitted the launch of Alzheimer's drug Aduhelm has been "slower than we anticipated." 
Via Investor's Business Daily
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.